UBS Group Boosts Cencora (NYSE:COR) Price Target to $335.00

Cencora (NYSE:COR - Get Free Report) had its price target upped by research analysts at UBS Group from $298.00 to $335.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. UBS Group's price objective would indicate a potential upside of 14.66% from the company's previous close.

Several other equities analysts have also issued reports on COR. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Bank of America raised their target price on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Wells Fargo & Company lifted their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Finally, Morgan Stanley set a $288.00 target price on shares of Cencora in a research note on Tuesday, April 15th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Cencora currently has a consensus rating of "Moderate Buy" and a consensus price target of $290.00.

Cencora Trading Up 0.6 %

COR traded up $1.74 during trading on Tuesday, reaching $292.17. 1,046,574 shares of the company's stock were exchanged, compared to its average volume of 1,511,470. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora has a one year low of $214.77 and a one year high of $296.65. The firm has a fifty day moving average price of $272.65 and a two-hundred day moving average price of $251.43. The stock has a market capitalization of $56.66 billion, a PE ratio of 41.56, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities research analysts forecast that Cencora will post 15.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the completion of the sale, the chairman now directly owns 315,913 shares of the company's stock, valued at $89,027,442.53. This trade represents a 4.41 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the transaction, the chief accounting officer now directly owns 20,154 shares in the company, valued at $5,241,249.24. This trade represents a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,223 shares of company stock worth $13,580,967. 10.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Cencora

Several institutional investors have recently bought and sold shares of the company. Hickory Asset Management Inc. purchased a new position in shares of Cencora during the 4th quarter valued at $572,000. Sylvest Advisors LLC purchased a new stake in Cencora during the fourth quarter valued at about $1,105,000. Insight Wealth Strategies LLC boosted its position in Cencora by 124.6% during the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company's stock worth $4,549,000 after purchasing an additional 11,232 shares during the period. Vontobel Holding Ltd. increased its stake in shares of Cencora by 46.9% in the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock worth $1,403,000 after purchasing an additional 1,995 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. raised its position in shares of Cencora by 71.1% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company's stock valued at $1,583,000 after purchasing an additional 2,928 shares during the period. Hedge funds and other institutional investors own 97.52% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.